# AL-S Pharma AG Names Harry Welten as CEO to Lead Phase 3 ALS Trial

- URL: https://stocks.freetheai.org/news/al-s-pharma-ag-names-harry-welten-as-ceo-to-lead-phase-3-als-trial-81579a
- Published: 2026-10-14T06:00:05Z
- Category: company_news; sentiment: neutral; impact: medium
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

AL-S Pharma AG has appointed Harry Welten as its new chief executive officer, succeeding Michael Salzmann. Welten takes charge as the biotechnology company prepares to advance its drug candidate, AP-101, into late-stage clinical development.

The leadership transition comes after encouraging Phase 2 trial results for AP-101, which targets misfolded SOD1 proteins in patients with amyotrophic lateral sclerosis (ALS). Conducting a pivotal Phase 3 study requires substantial financial resources, making Welten's focus on securing corporate partnerships and funding central to the company's growth strategy.

Investors and healthcare observers will watch for capital raises or strategic deals over the coming months. AL-S Pharma AG aims to begin the confirmatory Phase 3 ALS trial in 2027, which will serve as a key milestone for the development of AP-101.

## Key points

- Harry Welten takes over as CEO of AL-S Pharma AG, succeeding Michael Salzmann.
- The company is advancing its ALS treatment candidate AP-101 following positive Phase 2 trial results.
- A confirmatory Phase 3 trial for AP-101 is targeted to begin in 2027.
- Welten will focus on securing financing and business partnerships to fund the Phase 3 study.

## Questions and answers

### Who is the new CEO of AL-S Pharma AG?

Harry Welten was named CEO of AL-S Pharma AG, replacing former chief executive Michael Salzmann.

### What is AP-101 and what condition does it treat?

AP-101 is an experimental drug candidate designed to treat a specific subset of amyotrophic lateral sclerosis (ALS) by targeting misfolded SOD1 proteins.

### When will AL-S Pharma begin Phase 3 trials for AP-101?

AL-S Pharma AG plans to launch a confirmatory Phase 3 clinical trial for AP-101 in 2027.